Filtered By:
Specialty: Cytology
Cancer: Prostate Cancer
This page shows you your search results in order of date.
Order by Relevance | Date
Total 535 results found since Jan 2013.
Suppression of tumor cell lactate-generating signaling pathways eradicates murine PTEN/p53-deficient aggressive-variant prostate cancer via macrophage phagocytosis
CONCLUSIONS: Abrogation of lactate-mediated cross-talk between cancer cells and TAM results in durable ADT-independent tumor control in PTEN/p53-deficient AVPC, and warrants further investigation in clinical trials.PMID:37721526 | DOI:10.1158/1078-0432.CCR-23-1441
Source: Cell Research - September 18, 2023 Category: Cytology Authors: Kiranj Chaudagar Hanna M Hieromnimon Anne Kelley Brian Labadie Jordan Shafran Srikrishnan Rameshbabu Catherine Drovetsky Kaela Bynoe Ani Solanki Erica Markiewicz Xiaobing Fan Massimo Loda Akash Patnaik Source Type: research
Evaluation of CD47 in the Suppressive Tumor Microenvironment and Immunotherapy in Prostate Cancer
CONCLUSION: Our research demonstrates a closely relationship among CD47 and the immunological microenvironment of prostate cancer, and blocking CD47 can promote macrophages to phagocytosis of prostate cancer cells. Therefore, CD47 may provide novel strategies for potential immunotherapy of prostate cancer.PMID:37719086 | PMC:PMC10505079 | DOI:10.1155/2023/2473075
Source: Cell Research - September 18, 2023 Category: Cytology Authors: Qianqian Wang Chunxaing Feng Yuchun Chen Tianming Peng Yong Li Kunlin Wu Xiaoyong Pu Hanzhong Chen Jiumin Liu Source Type: research
F77 antigen is a promising target for adoptive T cell therapy of prostate cancer
This study entails the generation and evaluation of a second-generation CAR against a carbohydrate antigen on malignant prostate cancer cells. Using a single chain fragment variable (scFv) from an F77-specific mouse monoclonal antibody, we created second-generation CARs with CD28 and CD137 (4-1BB) costimulatory signals. F77 expressing lentiviral CAR T cells produce cytokines and kill tumor cells in a F77 expression-dependent manner. These F77-specific CAR T cells eradicate prostate tumors in a human xenograft model employing PC3 cells. These findings validate F77 as a promising immunotherapeutic target for prostate cancer ...
Source: Cell Research - September 17, 2023 Category: Cytology Authors: Payal Grover Selene Nunez-Cruz John Leferovich Tyra Wentz Atrish Bagchi Michael C Milone Mark I Greene Source Type: research
Reciprocal negative feedback regulation of ATF6 α and PTEN promotes prostate cancer progression
Cell Mol Life Sci. 2023 Sep 16;80(10):292. doi: 10.1007/s00018-023-04940-3.ABSTRACTPhosphatase and tensin homolog (PTEN) loss tightly correlates with prostate cancer (PCa) progression and metastasis. Inactivation of PTEN leads to abnormal activation of PI3K/AKT pathway. However, results from clinical trials with AKT inhibitors in PCa have been largely disappointing. Identification of novel regulators of PTEN in PTEN-dysfunctional PCa is urgently needed. Here we demonstrated that the expression level of PTEN is inversely correlated with the signature score of unfolded protein response (UPR) in PCa. Importantly, PTEN suppres...
Source: Cellular and Molecular Life Sciences : CMLS - September 16, 2023 Category: Cytology Authors: Tingting Feng Ru Zhao Hanwen Zhang Feifei Sun Jing Hu Meng Wang Mei Qi Ling Liu Lin Gao Yabo Xiao Junhui Zhen Weiwen Chen Lin Wang Bo Han Source Type: research
Comorbidity in patients with Lichen sclerosus: a retrospective cohort study
This study confirmed the association between LS and vulvar cancer (OR = 17.4; 95% CI 12.1-25.3), penis cancer (OR = 9.1; 95% CI 4.3-18.9), prostate cancer (OR = 2.0; 95% CI 1.6-2.4) and breast cancer (OR = 1.6; 95% CI 1.4-1.8). LS was also associated with Crohn´s disease (OR = 2.0; 95% CI 1.6-2.6) and diabetes mellitus type 1 (OR = 1.9; 95% CI 1.6-2.1). The present study revealed novel important data regarding the association of LS with cancer and autoimmune diseases, emphasising the importance of sufficient treatment and follow-up of patients with LS. However, future studies are needed to confirm these results and the po...
Source: Cell Research - September 12, 2023 Category: Cytology Authors: Sandra Jerkovic Gulin Filippa Lundin Oliver Seifert Source Type: research
LMNTD2-AS1 regulates immune cell infiltration and promotes prostate cancer progression by targeting FUS to regulate NRF2 signal pathway
This study aimed to identify lncRNAs associated with overall survival (OS) and progression-free interval (PFI) in prostate cancer (PCa) patients and to elucidate the driving mechanisms and functions of these lncRNAs. We utilized the TCGA database to screen for lncRNAs linked with OS and PFI. KM survival analysis, ROC curve analysis, and Cox survival analysis were employed to assess the prognostic significance of lncRNAs in PCa patients. We conducted a loss-of-function assay to explore the role of lncRNAs in PCa. Correlation analysis was performed to study the relationship between lncRNAs and immune cell infiltration. Lasso...
Source: Cell Research - September 11, 2023 Category: Cytology Authors: Haoming Wu Ning Liu Aifeng He Haiyang Li Hui Liu Jinke Qian Weipu Mao Guangbo Fu Source Type: research
Androgen deprivation therapy caused a drastic proliferation of B-cell lymphoma with IgG4-related disease in patients with prostate cancer: a case report
CONCLUSION: This case is the first report of clinical significance regarding the crucial role of estrogen and estrogen receptor β in malignant lymphoma in a patient with IgG4-related disease. Our report aims to raise awareness of the need to carefully select treatment options for prostate cancer patients with IgG4-related disease or lymphoma.PMID:37688628 | DOI:10.1007/s00432-023-05292-y
Source: Cell Research - September 9, 2023 Category: Cytology Authors: Hajime Sasagawa Kazuyuki Numakura Mizuki Mori Mizuki Kobayashi Soki Kashima Ryohei Yamamoto Taketoshi Nara Mitsuru Saito Shintaro Narita Hiroshi Nanjo Tomonori Habuchi Source Type: research
Epigenetic mechanism of therapeutic resistance and potential of epigenetic therapeutics in chemorefractory prostate cancer
Int Rev Cell Mol Biol. 2023;380:173-210. doi: 10.1016/bs.ircmb.2023.03.012. Epub 2023 Apr 12.ABSTRACTProstate cancer is the second leading cause of cancer death among men in the United States. Depending upon the histopathological subtypes of prostate cancers, various therapeutic options, such as androgen deprivation therapy (ADT), androgen receptor signaling inhibitors (ARSI), immunotherapy, and chemotherapy, are available to treat prostate cancer. While these therapeutics are effective in the initial stages during treatments, the tumors subsequently develop resistance to these therapies. Despite all the progress made so f...
Source: International Review of Cell and Molecular Biology - September 1, 2023 Category: Cytology Authors: Priti Roy Kamaleshwar P Singh Source Type: research
